Publication Name	World Journal of Clinical Oncology
Manuscript ID	45554
Country	Germany

Received	2019-02-28 01:27
Peer-Review Started	2019-03-04 10:50
To Make the First Decision	2019-04-12 00:50
Return for Revision	2019-04-24 09:30
Revised	2019-07-03 14:15
Second Decision	2019-07-12 10:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-07-16 17:14
Articles in Press	2019-07-16 17:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-07-24 02:52
Publish the Manuscript Online	2019-07-24 07:32

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Mona Passler, Eliane Tabea Taube, Jalid Sehouli and Klaus Pietzner
ORCID	Author(s) ORCID Number Mona Passler http://orcid.org/0000-0001-5674-201X Eliane Tabea Taube http://orcid.org/0000-0003-3041-694X Jalid Sehouli http://orcid.org/0000-0002-5963-6623 Klaus Pietzner http://orcid.org/0000-0003-2056-1668
Funding Agency and Grant Number
Corresponding Author	Mona Passler, Department of Gynecology, Competence Center for Ovarian Cancer (EKZE), Charité - University Medicine, Augustenburger Platz 1, Berlin 13353, Germany. mona.passler@charite.de
Key Words	Case report; Nivolumab; Clinical oncology; Checkpoint inhibition; Gynecologic oncology; Pseudoprogression
Core Tip	Clinicians have to be aware of the phenomenon of pseudoprogression despite its rather rare occurrence. As both- pseudoprogression and real progression present with an increase in tumor size, the only certain way to differentiate between them is the occurrence of infiltrating growth. While the increase of tumor size in pseudoprogression can be explained by benign growth due to immune cell infiltration and edema, only malign growth of a real progression has the ability to infiltrate other tissues. When in doubt whether a pseudoprogression has occurred, we suggest cautious continuation of checkpoint-inhibition paired with corticoids to lower adverse effects if necessary.
Publish Date	2019-07-24 07:32
Citation	Passler M, Taube ET, Sehouli J, Pietzner K. Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report. World J Clin Oncol 2019;10(7): 247-255
URL	https://www.wjgnet.com/2218-4333/full/v10/i7/247.htm
DOI	https://dx.doi.org/10.5306/wjco.v10.i7.247

Full Article (PDF)	WJCO-10-247.pdf
Full Article (Word)	WJCO-10-247.docx
Manuscript File	45554-Review.docx
Answering Reviewers	45554-Answering reviewers.pdf
Audio Core Tip	45554-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	45554-Conflict-of-interest statement.pdf
Copyright License Agreement	45554-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	45554-Informed consent statement.pdf
Peer-review Report	45554-Peer-review(s).pdf
Scientific Misconduct Check	45554-Scientific misconduct check.pdf
Scientific Editor Work List	45554-Scientific editor work list.pdf